Renal Artery Stenosis With Flash Pulmonary Edema: Confirming Medical Therapy Has Actually Failed
The major trials found no benefit to stenting over medical therapy for most patients with this finding — but her flash pulmonary edema and still-refractory blood pressure fall outside the population those trials specifically isolated.
B.C., a 66-year-old woman, has managed her hypertension the way she managed her clients' finances for thirty years — carefully, with a notebook of her home blood pressure readings she brings to every visit. Despite that discipline and four antihypertensive medications at meaningful doses, her blood pressure has stayed above goal for over a year, and three weeks ago she was hospitalized with sudden shortness of breath and pulmonary edema that resolved quickly with diuresis and had no clear cardiac cause — a pattern her nephrologist recognized as flash pulmonary edema rather than a routine heart failure exacerbation.
Her workup found a 75% atherosclerotic stenosis in her left renal artery, with normal-appearing anatomy on the right — and that detail cuts against the tidy story. Flash pulmonary edema attributed to renovascular disease was described in bilateral stenosis or in stenosis of a solitary functioning kidney, where no normal kidney remains to excrete the retained sodium and water. With one patent renal artery and a healthy kidney behind it, the mechanism is much harder to invoke, and the attribution has to be held more loosely than the phrase 'flash pulmonary edema' usually invites. The evidence on renal artery stenting has moved substantially over the past two decades: CORAL, following ASTRAL before it, found no meaningful benefit of stenting over optimal medical therapy for blood pressure control or renal function preservation in the broad population of patients with atherosclerotic renal artery stenosis, and that finding has appropriately shifted most patients toward medical management as the default. What CORAL's population didn't specifically isolate, though, are patients like her: refractory hypertension despite genuinely maximized therapy, combined with flash pulmonary edema, a specific clinical syndrome some nephrology and vascular literature continues to treat as a scenario where stenting may still offer real benefit, distinct from the broad population the major trials studied.
In the nephrology clinic, after the hospitalization
CORAL was a well-conducted trial and I take its result seriously — for most patients with atherosclerotic renal artery stenosis, stenting doesn't add benefit over optimal medical therapy, and that should remain the default. But she isn't the average CORAL patient. Flash pulmonary edema combined with genuinely refractory hypertension is a specific clinical picture that the major negative trials didn't isolate as its own subgroup, and where some literature outside those trials still supports a real benefit from revascularization. I'll concede the weak point in my own argument: that syndrome is described in bilateral disease or a solitary kidney, and hers is unilateral with a normal right kidney, which makes attributing the episode to the stenosis a genuine assumption rather than a finding.
If her hypertension were simply difficult rather than refractory on truly maximized therapy, or if she'd never had the pulmonary edema episode, I would be squarely in the CORAL-supported camp of medical therapy alone — the case for stenting here rests specifically on those two findings together, not on the stenosis itself.
I want to make sure 'refractory' is actually confirmed rather than assumed before we act on it. Four medications doesn't automatically mean maximized therapy if any of the doses have room to increase, and I'd want to see her regimen pushed to true target doses, plus confirm she doesn't have an unaddressed component like sleep apnea or medication timing issues, before concluding medical therapy has genuinely failed her.
I'm not disputing that her pulmonary edema episode is a real, specific red flag — it clearly is. I just want the medical-therapy side of the ledger to be unambiguously maximized before weighing it against a procedure, so that if we do proceed to stenting, it's clearly justified rather than a reach because her regimen still had room to grow.
That's a fair check to run first. I'd uptitrate her ACE inhibitor and thiazide to their maximum labeled doses — checking creatinine and potassium one to two weeks after each increase, since she has renal artery stenosis, an eGFR of 58, and spironolactone already on board, and that combination is where a manageable regimen turns into acute kidney injury or hyperkalemia without warning. I'd add a beta-blocker as a fifth agent, chosen for renin suppression rather than for her pulmonary edema episode specifically, and screen for obstructive sleep apnea given how common it is in resistant hypertension and how often it's missed. If her blood pressure remains refractory and especially if she has another pulmonary edema episode despite that genuinely maximized regimen, the case for renal artery stenting becomes considerably stronger and better-justified than it is today.
Agreed: ACE inhibitor and thiazide uptitrated to maximum labeled doses, a beta-blocker added as a fifth agent, and a sleep study ordered — with renal artery stenting held explicitly in reserve rather than either adopted now or ruled out permanently.
Medical management continues as the long-term plan, consistent with what CORAL supports for the broader population.
Renal artery stenting moves forward, justified by findings the major negative trials didn't specifically isolate.
Either way, her own blood pressure log will be part of how that judgment gets made, not just office measurements.